investiment.io
Adicet Bio, Inc.
$0.92
0.02 (1.89%)
Adicet Bio, Inc.
$0.92
0.02 (1.89%)
0HX7.L Price Chart
| Basic | |
|---|---|
| Market Cap | $79.4M |
| Price | $0.92 |
| 52 Week Range | 0.9115-7.6 |
| Beta | 1.70 |
| Margins | |
| Gross Profit Margin | 61.67% |
| Operating Profit Margin | -996.11% |
| Net Profit Margin | -914.25% |
| Valuation (TTM) | |
| P/E Ratio | -0.72 |
| Price to Sales Ratio | 5.94 |
| Price to Book Ratio | 0.40 |
| PEG Ratio | -0.02 |
Industry
Medical - Pharmaceuticals
Sector
Healthcare
Full-Time Employees
143
Website
IPO Date
2021-01-08T00:00:00.000Z
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Phone
650 503 9095
Address
200 Clarendon Street, Boston, MA, 02116, US